I haven't really seen anything on this since Patrick (pjoshea13) had written about it a few years ago: healthunlocked.com/advanced...
Has anyone discussed it with their docs? I plan to, later this week. I guess a few small trials are tentatively showing a potential benefit? I just stumbled upon this editorial, too, which I severely edited down to mostly plain English below, lol: urotoday.com/center-of-exce...
"Recall that abiraterone is not a complicated molecule, it is simply a slightly altered version of progesterone, a naturally occurring hormone.
In a paper published in June of 2018, a team led by Nima Sharifi from the Cleveland Clinic identified that certain metabolites of abiraterone are AR agonists. As such, abiraterone metabolism creates its own competitor, in a manner of speaking... [by producing] 3-keto-5-beta abira abiraterone [which] ends up as an androgen agonist, thus potentially mitigating the antitumor potency.
The enzyme that catalyzes the conversion of D4 abiraterone to 3-keto-5-alpha abiraterone is 5 alpha reductase, the very enzyme that could be catabolized by the addition of a 5 alpha-reductase inhibitor such as finasteride or dutasteride. Although such treatments have not resulted in substantial antitumor activity, they have not been studied in this context.
One possibility is that we could combine abiraterone with 5 alpha reductase inhibitors. This has been done on a small scale but not based on the genetics of polymorphisms."
Written by: Charles Ryan, MD, B.J. Kennedy Chair in Clinical Medical Oncology, Director and Professor of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota -- Published Date: July 11th, 2018
Patrick (pjoshea13) has also written about the potential benefits of 5a-reductase inhibitors coming with potential RISKS, too. But doesn't it seem to make sense to use one with long-term abiraterone treatment?